Champions Oncology, Inc. (CSBR) Cash Flow Statement
Where CSBR’s cash came from and went, FY2026
April 30, 2026 · U.S. dollars- Cash from operations
- −$4.5M −160.5% vs FY2025
- Capital expenditures
- $564,000 0.9% of revenue
- Free cash flow
- −$5.0M −8.5% margin
- Returned to shareholders
- —
- Change in cash
- −$4.9M cash at year-end $4.9M
Cash from operations
−$4.5M
Capital expenditures
−$564,000
Acquisitions & other
+$24,000
Net borrowing (repayment)
−$135,000
Other financing
+$234,000
Change in cash
−$4.9M
Drawn to scale: where the cash came from and how it was used. Hover for values.
CSBR operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
CSBR cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$2.8MFY2017 | −$4.5MFY2026 | — | |
| Capital expenditures | $766,000FY2017 | $564,000FY2026 | −3.3%/yr | |
| Free cash flow | −$3.6MFY2017 | −$5.0MFY2026 | — | |
| Free cash flow margin | −23.4%FY2017 | −8.5%FY2026 | +14.9 pts | |
| Operating cash flow / net income | 14.55FY2019 | 1.57FY2025 | −12.98 | |
| Stock-based compensation | $2.7MFY2017 | $1.2MFY2026 | −8.2%/yr | |
| Dividends paid | $0FY2017 | $0FY2018 | — | |
| Share buybacks (net) | $0FY2017 | $0FY2025 | — | |
| Capex / revenue | 5.0%FY2017 | 0.9%FY2026 | −4.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CSBR cash flow by activity
OperatingInvestingFinancingChange in cash
CSBR net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
CSBR cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$1.2M | $4.7M | −$7.3M | −$5.3M | $548,000 | $334,000 | −$2.0M | $128,000 | −$1.5M | −$6.9M |
| Depreciation & amortization | $1.4M | $1.6M | $1.9M | $2.2M | $1.6M | $1.2M | $825,000 | $606,000 | $360,000 | $168,000 |
| Stock-based compensation | $1.2M | $654,000 | $1.1M | $864,000 | $912,000 | $598,000 | $600,000 | $636,000 | $1.0M | $2.7M |
| Change in working capital | −$7.4M | −$621,000 | −$3.8M | $4.2M | $2.3M | −$4.2M | $2.5M | $11,000 | −$1.5M | $1.1M |
| Other non-cash items | $1.5M | $1.0M | $2.0M | $1.9M | $1.1M | $372,000 | $963,000 | $481,000 | $447,000 | $68,000 |
| Cash from operating activities | −$4.5M | $7.4M | −$6.1M | $4.0M | $6.5M | −$1.7M | $2.9M | $1.9M | −$1.2M | −$2.8M |
| Investing activities | ||||||||||
| Capital expenditures | −$564,000 | −$389,000 | −$836,000 | −$2.9M | −$2.4M | −$3.3M | −$2.2M | −$834,000 | −$1.2M | −$766,000 |
| Investments (net) | — | −$389,000 | −$836,000 | −$2.9M | −$2.4M | −$3.2M | −$2.2M | −$834,000 | −$1.2M | −$766,000 |
| Acquisitions & other investing | $24,000 | $389,000 | $836,000 | $2.9M | $2.4M | $3.3M | $2.2M | $834,000 | $1.2M | $766,000 |
| Cash from investing activities | −$540,000 | −$389,000 | −$836,000 | −$2.9M | −$2.4M | −$3.2M | −$2.2M | −$834,000 | −$1.2M | −$766,000 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share repurchases & issuance (net) | — | $0 | −$634,000 | −$74,000 | $207,000 | $1.4M | $4.5M | $1.5M | $38,000 | $4.3M |
| Net borrowing (repayment) | −$135,000 | −$150,000 | −$146,000 | $0 | $0 | −$174,000 | −$35,000 | −$262,000 | −$25,000 | −$24,000 |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $234,000 | $320,000 | $253,000 | $85,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash from financing activities | $99,000 | $170,000 | −$527,000 | $11,000 | $207,000 | $1.2M | $4.4M | $1.2M | $13,000 | $4.3M |
| Summary | ||||||||||
| Net change in cash | −$4.9M | $7.2M | −$7.5M | $1.1M | $4.3M | −$3.7M | $5.1M | $2.2M | −$2.4M | $710,000 |
| Cash at end of period | $4.9M | $9.8M | $2.6M | $10.1M | $9.0M | $4.7M | $8.3M | $3.2M | $856,000 | $3.3M |
| Free cash flow | −$5.0M | $7.0M | −$7.0M | $1.1M | $4.1M | −$5.0M | $685,000 | $1.0M | −$2.5M | −$3.6M |
| Free cash flow margin | −8.5% | 12.3% | −13.9% | 2.0% | 8.4% | −12.1% | 2.1% | 3.8% | −12.1% | −23.4% |
| Capex / revenue | 0.9% | 0.7% | 1.7% | 5.3% | 4.9% | 8.0% | 6.9% | 3.1% | 6.1% | 5.0% |
| Operating cash flow / net income | — | 1.57 | — | — | 11.86 | −5.03 | — | 14.55 | — | — |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$426,000 | −$667,000 | −$278,000 | $236,000 | −$466,000 | −$1.8M | $4.5M | $728,000 | $1.3M | −$109,000 | −$2.5M | −$2.1M |
| Depreciation & amortization | $314,000 | $321,000 | $341,000 | $357,000 | $358,000 | $394,000 | $398,000 | $399,000 | $449,000 | $457,000 | $481,000 | $484,000 |
| Stock-based compensation | $766,000 | $357,000 | $423,000 | $249,000 | $208,000 | $131,000 | $256,000 | $9,000 | $258,000 | $263,000 | $379,000 | $53,000 |
| Change in working capital | −$1.4M | −$2.4M | $2.8M | −$3.0M | $199,000 | $7.7M | −$4.9M | −$1.5M | −$1.9M | −$3.2M | $375,000 | $1.8M |
| Other non-cash items | $275,000 | $403,000 | −$4.6M | $428,000 | $301,000 | $451,000 | $258,000 | $85,000 | $218,000 | $800,000 | $376,000 | $370,000 |
| Cash from operating activities | −$492,000 | −$2.0M | −$1.3M | −$1.7M | $600,000 | $6.9M | $490,000 | −$283,000 | $311,000 | −$1.8M | −$919,000 | $589,000 |
| Investing activities | ||||||||||||
| Capital expenditures | −$55,000 | −$239,000 | −$37,000 | −$242,000 | −$46,000 | −$253,000 | −$42,000 | −$94,000 | $0 | −$111,000 | −$126,000 | −$153,000 |
| Investments (net) | — | — | — | — | −$46,000 | −$253,000 | −$42,000 | −$94,000 | $0 | $111,000 | −$126,000 | −$153,000 |
| Acquisitions & other investing | $0 | $1,000 | $23,000 | $0 | $46,000 | $253,000 | $42,000 | $94,000 | — | $111,000 | $160,000 | $153,000 |
| Cash from investing activities | −$55,000 | −$238,000 | −$14,000 | −$242,000 | −$46,000 | −$253,000 | −$42,000 | −$94,000 | — | $111,000 | −$92,000 | −$153,000 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | −$32,000 |
| Net borrowing (repayment) | −$19,000 | −$19,000 | −$39,000 | −$39,000 | −$38,000 | −$38,000 | −$38,000 | −$37,000 | −$37,000 | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $52,000 | $0 | $3,000 | $207,000 | $24,000 | $6,000 | $38,000 | $276,000 | $0 | −$145,000 | −$34,000 | $240,000 |
| Cash from financing activities | $33,000 | −$19,000 | −$36,000 | $168,000 | −$14,000 | −$32,000 | $0 | $239,000 | −$37,000 | −$145,000 | −$34,000 | $208,000 |
| Summary | ||||||||||||
| Net change in cash | −$514,000 | −$2.3M | −$1.4M | −$1.8M | $540,000 | $6.6M | $448,000 | −$138,000 | $274,000 | −$1.9M | −$1.0M | $644,000 |
| Cash at end of period | $4.4M | $4.9M | $7.1M | $8.5M | $10.3M | $9.8M | $3.2M | $2.8M | $2.9M | $2.6M | $4.5M | $5.5M |
| Free cash flow | −$547,000 | −$2.2M | −$1.4M | −$2.0M | $554,000 | $6.6M | $448,000 | −$377,000 | $311,000 | −$1.7M | −$1.0M | $436,000 |
| Free cash flow margin | −3.6% | −16.2% | −8.3% | −13.1% | 4.0% | 53.5% | 2.6% | −2.8% | 2.2% | −12.2% | −8.7% | 3.8% |
| Capex / revenue | 0.4% | 1.7% | 0.2% | 1.6% | 0.3% | 2.0% | 0.2% | 0.7% | 0.0% | 0.8% | 1.0% | 1.3% |
| Operating cash flow / net income | — | — | — | −7.35 | — | — | 0.11 | −0.39 | 0.24 | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
CSBR cash generation
In fiscal 2026 (ended April 30, 2026), Champions Oncology generated -$4.5 million of cash from operations (down 160.5%) and spent $0.6 million on capital expenditures, leaving free cash flow of -$5.0 million, −8.5% of revenue. Cash and equivalents fell by $4.9 million over the year.
Related: CSBR income statement, CSBR balance sheet. See the CSBR stock overview for the latest quote and news.
CSBR cash flow FAQ
What is Champions Oncology's free cash flow?
Champions Oncology's free cash flow was -$5.0 million in fiscal 2026: -$4.5 million of operating cash flow minus $0.6 million of capital expenditures It was $7.0 million a year earlier..
How much cash does Champions Oncology generate from operations?
Champions Oncology generated -$4.5 million of cash from operating activities in fiscal 2026.
How much does Champions Oncology spend on capital expenditures?
Champions Oncology spent $0.6 million on capital expenditures in fiscal 2026, 0.9% of revenue, compared with $0.4 million the year before.